Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
J Dermatolog Treat ; 26(3): 291-6, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25034003

ABSTRACT

INTRODUCTION: Atopic dermatitis (AD) is a chronic inflammatory skin disease. Sodium cromoglicate (SCG) is a chromone with anti-inflammatory, anti-itch and anti-allergic activity. This trial is a 12-week comparison (RCT) of a 4% SCG cutaneous emulsion with its vehicle in AD. MATERIALS AND METHODS: 208 children aged 2-12 years participated, 104 in each group. The primary endpoint was change in SCORAD score. Secondary endpoints included SASSAD score, topical steroid usage and global assessments. RESULTS: SCORAD was reduced by 28% (SCG group) and by 19% (vehicle): difference was statistically significant (p = 0.03) after 8 weeks and nearly significant (p = 0.09) after 12. A similar result occurred in SASSAD (p = 0.001 at 8 weeks). In subjects without major protocol deviations (SCG-64, vehicle-63), difference in SCORAD remained significant at 12 weeks (p = 0.04). Weight of topical steroids reduced in both groups: -0.60 ± 1.3 g/day (35%), SCG and -0.05 ± 1.1 g/day vehicle (p = 0.04). Treatment success, defined as investigator global opinion graded very or moderately effective, was significantly more frequent in SCG group (p = 0.025). Application site discomfort reported by 12.5% of subjects in SCG group and 16.5% in vehicle group. CONCLUSIONS: SCG 4% cutaneous emulsion provides an effective, well-tolerated, steroid-sparing treatment for AD in children.


Subject(s)
Anti-Allergic Agents/therapeutic use , Cromolyn Sodium/therapeutic use , Dermatitis, Atopic/drug therapy , Pruritus/drug therapy , Administration, Topical , Anti-Inflammatory Agents/therapeutic use , Child , Child, Preschool , Chronic Disease , Double-Blind Method , Female , Humans , Male , Treatment Outcome
4.
Contact Dermatitis ; 57(4): 203-10, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17868211

ABSTRACT

Hand eczema (HE) is one of the most frequent skin diseases and has often a chronically relapsing course with a poor prognosis resulting in a high social and economic impact for the individual and the society. In this article, we highlight the results of an expert workshop on the 'management of severe chronic hand eczema' with the focus on the epidemiology, the burden of severe HE, its classification and diagnostic procedures, and the current status of treatment options according to an evidence-based approach (randomized controlled clinical trials, RCTs). We conclude that despite the abundance of topical and systemic treatment options, disease management in patients with severe chronic HE is frequently inadequate. There is a strong need for RCTs of existing and new treatment options based on clearly diagnosed subtypes of HE and its severity.


Subject(s)
Eczema/therapy , Hand Dermatoses/therapy , Adrenal Cortex Hormones/therapeutic use , Chronic Disease , Cost of Illness , Dermatologic Agents/therapeutic use , Eczema/diagnosis , Eczema/epidemiology , Eczema/etiology , Environmental Exposure/adverse effects , Hand Dermatoses/diagnosis , Hand Dermatoses/epidemiology , Hand Dermatoses/etiology , Humans , Occupational Exposure/adverse effects , Phototherapy
5.
J Dermatolog Treat ; 18(4): 246-8, 2007.
Article in English | MEDLINE | ID: mdl-17671885

ABSTRACT

Necrobiosis lipoidica (NL) remains a major therapeutic challenge for the dermatologist and diabetologist. Amongst many treatment modalities attempted, systemic corticosteroids remain controversial, not least because a proportion of NL patients are diabetic, and corticosteroids are likely to destabilize their diabetic control. Close supervision as an inpatient is often required. We report the ambulatory outpatient management of an insulin-dependent diabetic with ulcerated necrobiosis lipoidica complicated by activated protein C resistance.


Subject(s)
Diabetes Mellitus, Type 1/complications , Glucocorticoids/administration & dosage , Necrobiosis Lipoidica/drug therapy , Prednisolone/administration & dosage , Adult , Diabetes Mellitus, Type 1/drug therapy , Female , Humans , Hypoglycemic Agents/administration & dosage , Insulin/administration & dosage , Insulin/analogs & derivatives , Lower Extremity/pathology , Necrobiosis Lipoidica/etiology , Necrobiosis Lipoidica/pathology , Skin/pathology
6.
J Dermatolog Treat ; 18(3): 175-7, 2007.
Article in English | MEDLINE | ID: mdl-17538807

ABSTRACT

Nail psoriasis is common in adult psoriatic patients and it causes serious psychological and physical distress. Topical treatments such as corticosteroids, calcipotriol, retinoids, and 5-fluorouracil have limited efficacy and are not without side effects. Relative effective systemic treatments are ciclosporin, methotrexate and acitretin, all of which have a serious toxicity potential. Biologics in the treatment of nail psoriasis have been the subject of recent research, but their cost-effectiveness is questionable. We present a case of psoriatic nail disease which improved greatly on treatment with fumaric acid esters (FAE).


Subject(s)
Dermatologic Agents/therapeutic use , Fumarates/therapeutic use , Nail Diseases/drug therapy , Psoriasis/drug therapy , Adult , Dermatologic Agents/administration & dosage , Fumarates/administration & dosage , Humans , Male , Nail Diseases/pathology , Psoriasis/pathology
7.
Eur J Dermatol ; 16(2): 167-71, 2006.
Article in English | MEDLINE | ID: mdl-16581570

ABSTRACT

Psoriasis treatment is highly individualized. Although a standardized assessment of psoriasis severity for clinical practice may be theoretically advantageous for the purposes of determining treatment, the relevance of currently available research tools in clinical practice is uncertain. Our objectives were to ascertain in workshop discussions and through a prospective survey the relevance of standard severity measures in clinical practice with regard to choice of treatment. Although there was agreement on the possible structure of an algorithm for the treatment-related definition of psoriasis severity, consensus on the cut-off levels for the PASI and %BSA that would indicate a switch in treatment mode could not be reached. The lack of agreement prompted a prospective survey of 112 patients with psoriasis from 10 countries. This survey used a formal questionnaire asking for the PASI and %BSA scores, the patient's self assessment score (VAS ranging from 0 to 10), location of the psoriatic lesions and disease phase. Severity scores from 20 patients pre-selected for inclusion in a trial of a biological agent were included for comparison. Severity scores were analysed in relation to the choice of treatment (topical or systemic, which included phototherapy and combination) suggested by the treating physician.PASI scores differed significantly between the treatment groups (topical vs systemic, p=0.009); however, there was large overlap in the range of PASI scores between the groups. The same was true for VAS scores (topical vs systemic, p=0.035). %BSA scores were not significantly different between treatment groups. There was a large overlap for both the topical and systemic treatment groups with the biologicals group for the range of both the PASI and %BSA scores. A standardized protocol for the evaluation of psoriasis severity based on established severity scores (PASI, %BSA) appears to be unrealistic in day-to-day clinical practice. In clinical practice, a host of factors must be evaluated alongside possible metric measures. This requires experience and the specialized medical education of those involved in the treatment of patients with psoriasis.


Subject(s)
Psoriasis/diagnosis , Humans , Prospective Studies , Severity of Illness Index , Surveys and Questionnaires
8.
J Dermatolog Treat ; 16(5-6): 258-77, 2005.
Article in English | MEDLINE | ID: mdl-16428145

ABSTRACT

Ciclosporin is a cyclic undecapeptide discovered in the 1970s to possess a potent inhibitory action on T lymphocytes. The subsequent discovery, in 1979, that it was remarkably effective in treatment of psoriasis transformed thinking about the nature of the disease, which subsequently became generally recognized as autoimmune in nature. Ciclosporin remains one of the most effective and rapidly acting treatments currently available for psoriasis. Virtually all the diverse manifestations of this disease can respond. The main side effects are nephrotoxicity and hypertension. There is considerable variation between individuals in susceptibility to these so careful monitoring is required. Ciclosporin should be used in single or intermittent short courses for all except the most severe cases as this is safer than continuous treatment. The rate of improvement depends very much on the dose, which ranges from 2 to 5.0 mg/kg/day. Ciclosporin can be combined with any topical treatment and a useful dose-sparing effect can be achieved in this way if patients are compliant. In severe cases ciclosporin is often used in combination with other systemic antipsoriatic drugs in order to spare the dose of each agent and reduce toxicity. Concurrent or intercurrent use of ultraviolet therapy is discouraged due to the increased risk of non-melanoma skin cancer. This article reviews the mode of action, pharmacokinetics, indications, contraindications, side effects, dosage regimens, pretreatment screening and monitoring, drug interactions, and use of treatment combinations with ciclosporin in the management of psoriasis.


Subject(s)
Cyclosporine/pharmacology , Cyclosporine/therapeutic use , Dermatologic Agents/pharmacology , Dermatologic Agents/therapeutic use , Psoriasis/drug therapy , Adult , Child , Cyclosporine/chemistry , Dermatologic Agents/chemistry , Female , Humans , Pregnancy
9.
BMJ ; 326(7403): 1367, 2003 Jun 21.
Article in English | MEDLINE | ID: mdl-12816824

ABSTRACT

OBJECTIVE: To explore the efficacy and safety of fluticasone propionate, cream and ointment, applied twice weekly in addition to maintenance treatment with emollients, in reducing the risk of relapse of chronic recurrent atopic dermatitis. DESIGN: Randomised, double blind, parallel group study of 20 weeks' duration. SETTING: Dermatology outpatient clinics (6 countries, 39 centres). PARTICIPANTS: Adult (aged 12-65) patients with moderate to severe atopic dermatitis who were experiencing a flare. METHODS: Participants applied fluticasone propionate (0.05% cream or 0.005% ointment; once or twice daily) regularly for four weeks to stabilise their condition. The patients whose disease was brought under control then continued into a 16 week maintenance phase, applying emollient on a daily basis with a bath oil as needed and either the same formulation of fluticasone propionate or its placebo base (emollient alone) twice weekly to the areas that were usually affected. MAIN OUTCOME MEASURE: Time to relapse of atopic dermatitis during maintenance phase. RESULTS: 376 patients entered the stabilisation phase, and 295 continued into the maintenance phase. After 16 weeks in the maintenance phase, the disease remained under control in 133 patients (87 using fluticasone propionate twice weekly, 46 using emollient alone), 135 (40 fluticasone propionate, 95 emollient) had experienced a relapse, and 27 had discontinued. Median time to relapse was six weeks for emollient alone compared with more than 16 weeks for additional fluticasone propionate. Patients who applied fluticasone propionate cream twice weekly were 5.8 times less likely (95% confidence interval 3.1 to 10.8, P < 0.001) and patients using fluticasone propionate ointment 1.9 times less likely (1.2 to 3.2, P=0.010) to have a relapse than patients applying emollient alone. The groups showed no differences in adverse events. CONCLUSION: After atopic dermatitis had been stabilised the addition of fluticasone propionate twice weekly to maintenance treatment with emollients significantly reduced the risk of relapse.


Subject(s)
Androstadienes/administration & dosage , Dermatitis, Atopic/prevention & control , Dermatologic Agents/administration & dosage , Adolescent , Adult , Aged , Androstadienes/adverse effects , Dermatologic Agents/adverse effects , Disease-Free Survival , Double-Blind Method , Drug Administration Schedule , Emollients/administration & dosage , Emollients/adverse effects , Fluticasone , Humans , Middle Aged , Risk Factors , Secondary Prevention , Treatment Outcome
10.
J Allergy Clin Immunol ; 109(3): 547-55, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11898005

ABSTRACT

BACKGROUND: Vehicle-controlled studies have demonstrated the efficacy and safety of tacrolimus ointment for patients with atopic dermatitis. OBJECTIVE: This study was undertaken to compare 0.03% and 0.1% tacrolimus ointment with 0.1% hydrocortisone-17-butyrate ointment, a midpotent to potent topical corticosteroid, in the treatment of adult patients with moderate-to-severe atopic dermatitis. METHODS: Patients applied ointment twice daily to all affected areas for 3 weeks in this multicenter, randomized, double-blind, parallel-group study. The primary endpoint was the modified eczema area and severity index (mEASI) mean area under the curve as a percentage of baseline. RESULTS: Five hundred seventy patients were randomized and received treatment. Discontinuations included 22 of 193 patients from the 0.03% tacrolimus group, 22 of 191 patients from the 0.1% tacrolimus group, and 17 of 186 patients from the hydrocortisone butyrate group. The median mEASI mean area under the curve as a percentage of baseline was 47.0%, 36.5%, and 36.1% for patients who received 0.03% tacrolimus, 0.1% tacrolimus, and 0.1% hydrocortisone butyrate, respectively. There was no statistically significant difference between 0.1% tacrolimus and 0.1% hydrocortisone butyrate; however, the lower improvement in mEASI for 0.03% tacrolimus was statistically significant when compared with 0.1% tacrolimus (P <.001) or hydrocortisone butyrate (P =.002). Skin burning and pruritus at the application site showed a higher incidence in the tacrolimus treatment groups than in the hydrocortisone butyrate group (P <.05). Laboratory parameters showed no treatment differences and no marked changes over time. CONCLUSIONS: The efficacy of 0.1% tacrolimus ointment was similar to that of 0.1% hydrocortisone butyrate ointment and was lower for 0.03% tacrolimus ointment. No serious safety concerns were identified.


Subject(s)
Dermatitis, Atopic/drug therapy , Hydrocortisone/therapeutic use , Immunosuppressive Agents/therapeutic use , Tacrolimus/therapeutic use , Administration, Topical , Adult , Double-Blind Method , Female , Humans , Hydrocortisone/administration & dosage , Hydrocortisone/adverse effects , Hydrocortisone/analogs & derivatives , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/adverse effects , Male , Ointments , Tacrolimus/administration & dosage , Tacrolimus/adverse effects , Treatment Outcome
11.
London; Mosby; 2002. xxiv,693 p. ilus, tab, 29cm.
Monography in English | LILACS, HANSEN, Hanseníase Leprosy, SESSP-ILSLACERVO, Sec. Est. Saúde SP | ID: biblio-1086435
SELECTION OF CITATIONS
SEARCH DETAIL
...